Dynport Vaccine Company LLC, a CSC company (DVC) is the prime systems contractor for the US Department of Defense Joint Vaccine Acquisition Program (JVAP) and is responsible for the advanced development and licensure with the Food and Drug Administration (FDA) of vaccines and other biological products designed to protect against a variety of biological agents.
As part of this program, a recombinant vaccine for protection against pneumonic plague is undergoing advanced development by DVC. The antigenic component of this vaccine is a single protein produced from a fusion of the Yersinia pestis genes for the F1 capsular protein and the V virulence protein. The product is currently being investigated in the US under a DVC-sponsored IND.
DVC is seeking the technical services for purification and concentration of IgG from human, cynomolgus macaque and mouse serum collected following vaccination with the recombinant plague vaccine (immune serum) as well as normal (naïve) serum from each species. Work must be performed using Good Laboratory Practices or Good Documentation Practices.
Objectives
1.1 Purify and concentrate IgG from human, cynomolgus macaque and mouse immune and naïve sera.
1.2 Perform a detection assay to quantify the amount of IgG following purification and concentration.
1.3 Purified and concentrated IgG must be in a final buffer that allows the purified IgG to be injected into mice.
Please respond to this Sources Sought with your capabilities/past performance and interest to Jo Ann Brown, Principal Subcontract Administrator, DVC at [email protected]